GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Net Income

OptimizeRx (OptimizeRx) Net Income : $-17.57 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. OptimizeRx's Net Income for the three months ended in Dec. 2023 was $-4.14 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-17.57 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. OptimizeRx's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.23.


OptimizeRx Net Income Historical Data

The historical data trend for OptimizeRx's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Net Income Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.14 -2.21 0.38 -11.44 -17.57

OptimizeRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -6.40 -4.16 -2.87 -4.14

OptimizeRx Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

OptimizeRx's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-25.164+7.598+0+3.5527136788005E-15
=-17.57

OptimizeRx's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-11.739+7.598+0+8.8817841970013E-16
=-4.14

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OptimizeRx  (NAS:OPRX) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

OptimizeRx's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


OptimizeRx Net Income Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022

OptimizeRx (OptimizeRx) Headlines